Lower lymphocyte counts and older age are associated with reduced multiple sclerosis disease activity during dimethyl fumarate treatment

Patient-specific factors modulate leukocyte response in dimethyl fumarate treated MS patients

(2020) Myla D. Goldman et al.   PLoS One

Fingolimod and Dimethyl-Fumarate-Derived Lymphopenia is not Associated with Short-Term Treatment Response and Risk of Infections in a Real-Life MS Population

(2020) Giacomo Boffa et al.   CNS DRUGS

Effect of dimethyl fumarate on lymphocytes in RRMS

(2019) Devangi Mehta et al.   NEUROLOGY

Factors associated with dimethyl fumarate-induced lymphopenia

(2019) Susana Sainz de la Maza et al.   JOURNAL OF THE NEUROLOGICAL SCIENCES

Lymphocyte Count and Body Mass Index as Biomarkers of Early Treatment Response in a Multiple Sclerosis Dimethyl Fumarate-Treated Cohort

(2019) Alessia Manni et al.   Frontiers in Immunology

Risk factors for lymphopenia in patients with relapsing–remitting multiple sclerosis treated with dimethyl fumarate

(2019) Fabian Sierra Morales et al.   JOURNAL OF NEUROLOGY

Genetic Study of Severe Prolonged Lymphopenia in Multiple Sclerosis Patients Treated With Dimethyl Fumarate

(2019) Dipen Sangurdekar et al.   Frontiers in Genetics

Clinical predictors of Dimethyl Fumarate response in multiple sclerosis: a real life multicentre study

(2019) R. Lanzillo et al.   Multiple Sclerosis and Related Disorders

The influence and impact of ageing and immunosenescence (ISC) on adaptive immunity during multiple sclerosis (MS) and the animal counterpart experimental autoimmune encephalomyelitis (EAE)

(2018) Christopher Bolton et al.   AGEING RESEARCH REVIEWS

Safety and Efficacy of Dimethyl Fumarate in Multiple Sclerosis: An Italian, Multicenter, Real-World Study

(2018) Massimiliano Mirabella et al.   CNS DRUGS

Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria

(2018) Alan J Thompson et al.   LANCET NEUROLOGY

Diffuse dermatophytosis occurring on dimethyl fumarate therapy

(2018) Jeffrey I Greenstein   Multiple Sclerosis Journal

Diffuse dermatophytosis occurring on dimethyl fumarate therapy

(2018) Jeffrey I Greenstein   Multiple Sclerosis Journal

Predictors of hematological abnormalities in multiple sclerosis patients treated with fingolimod and dimethyl fumarate and impact of treatment switch on lymphocyte and leukocyte count

(2018) M. Baharnoori et al.   Multiple Sclerosis and Related Disorders

Emerging Understanding of the Mechanism of Action for Dimethyl Fumarate in the Treatment of Multiple Sclerosis

(2018) Elizabeth A. Mills et al.   Frontiers in Neurology

Herpes simplex virus encephalitis temporally associated with dimethyl fumarate-induced lymphopenia in a multiple sclerosis patient

(2018) Paola Perini et al.   Multiple Sclerosis and Related Disorders

Lymphopenia and risk of infection and infection-related death in 98,344 individuals from a prospective Danish population-based study

(2018) Marie Warny et al.   PLOS MEDICINE

Progressive multifocal leukoencephalopathy in patients treated with fumaric acid esters: a review of 19 cases

(2017) Robbert-Jan Gieselbach et al.   JOURNAL OF NEUROLOGY

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

(2017) Vinzenz Fleischer et al.   Multiple Sclerosis Journal

Treatment response to dimethyl fumarate is characterized by disproportionate CD8+ T cell reduction in MS

(2017) Vinzenz Fleischer et al.   Multiple Sclerosis Journal

Dimethyl fumarate associated lymphopenia in clinical practice

(2014) Erin E Longbrake et al.   Multiple Sclerosis Journal